GEN Exclusives

More »

GEN News Highlights

More »
Feb 26, 2009

Cyclogenix Inks License and Research Deals Wyeth and IMBcom to Further Peptide Research

  • Cyclogenix licensed its peptide discovery platform to Wyeth Pharmaceuticals and separately obtained rights to technology developed by IMBcom to advance its own peptide therapeutic focus.

    Under the license agreement, Wyeth will be able to generate therapeutic peptides and will have the option to acquire all rights and ownership at the end of the agreement term, which may last up to five years, or earlier if certain conditions are met.

    IMBcom, the University of Queensland's (UQ) company for commercializing technology from the Institute for Molecular Bioscience (IMB), will license cyclotide peptide technologies to Cyclogenix to develop a cyclotdie-based drug. Additionally, under a research partnership, David Craik, a UQ professor, will collaborate with the company to develop these drug candidates.

    "We believe that combining the novel properties of the cyclotide scaffold with Cyclogenix's expertise in display technologies, provides a powerful new approach for the potential discovery of novel peptides for therapeutic applications," says Dr. Duncan McGregor, Ph. D., CEO of Cyclogenix.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Tackling the Global Problem of Fake Medicines

Policy proposals to address the growing global problem of fake medicines include a global agreement, similar to the Framework Convention on Tobacco Control, and stricter national laws to prosecute those who knowingly sell counterfeit medicines. Do you think these steps will be successful?

More »